Anti-Inflammatory Effects of Cumin Essential Oil by Blocking JNK, ERK, and NF- κ

Cumin seeds (Cuminum cyminum L.) have been commonly used in food flavoring and perfumery. In this study, cumin essential oil (CuEO) extracted from seeds was employed to investigate the anti-inflammatory effects in lipopolysaccharide- (LPS-) stimulated RAW 264.7 cells and the underlying mechanisms. A total of 26 volatile constituents were identified in CuEO by GC-MS, and the most abundant constituent was cuminaldehyde (48.773%). Mitochondrial-respiration-dependent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction assay demonstrated that CuEO did not exhibit any cytotoxic effect at the employed concentrations (0.0005–0.01%). Real-time PCR tests showed that CuEO significantly inhibited the mRNA expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX-2), interleukin- (IL-) 1, and IL-6. Moreover, western blotting analysis revealed that CuEO blocked LPS-induced transcriptional activation of nuclear factor-kappa B (NF-κB) and inhibited the phosphorylation of extracellular signal regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). These results suggested that CuEO exerted anti-inflammatory effects in LPS-stimulated RAW 264.7 cells via inhibition of NF-κB and mitogen-activated protein kinases ERK and JNK signaling; the chemical could be used as a source of anti-inflammatory agents as well as dietary complement for health promotion

Towards Persona-Based Empathetic Conversational Models

Empathetic conversational models have been shown to improve user satisfaction and task outcomes in numerous domains. In Psychology, persona has been shown to be highly correlated to personality, which in turn influences empathy. In addition, our empirical analysis also suggests that persona plays an important role in empathetic conversations. To this end, we propose a new task towards persona-based empathetic conversations and present the first empirical study on the impact of persona on empathetic responding. Specifically, we first present a novel large-scale multi-domain dataset for persona-based empathetic conversations. We then propose CoBERT, an efficient BERT-based response selection model that obtains the state-of-the-art performance on our dataset. Finally, we conduct extensive experiments to investigate the impact of persona on empathetic responding. Notably, our results show that persona improves empathetic responding more when CoBERT is trained on empathetic conversations than non-empathetic ones, establishing an empirical link between persona and empathy in human conversations.Comment: Accepted to EMNLP 2020 (A new dataset is proposed: https://github.com/zhongpeixiang/PEC

CARE: Commonsense-Aware Emotional Response Generation with Latent Concepts

Rationality and emotion are two fundamental elements of humans. Endowing agents with rationality and emotion has been one of the major milestones in AI. However, in the field of conversational AI, most existing models only specialize in one aspect and neglect the other, which often leads to dull or unrelated responses. In this paper, we hypothesize that combining rationality and emotion into conversational agents can improve response quality. To test the hypothesis, we focus on one fundamental aspect of rationality, i.e., commonsense, and propose CARE, a novel model for commonsense-aware emotional response generation. Specifically, we first propose a framework to learn and construct commonsense-aware emotional latent concepts of the response given an input message and a desired emotion. We then propose three methods to collaboratively incorporate the latent concepts into response generation. Experimental results on two large-scale datasets support our hypothesis and show that our model can produce more accurate and commonsense-aware emotional responses and achieve better human ratings than state-of-the-art models that only specialize in one aspect.Comment: AAAI-202

Sugarcane bagasse dietary fiber as an adjuvant therapy for stable chronic obstructive pulmonary disease: a four-center, randomized, double-blind, placebo-controlled study

AbstractObjectiveTo evaluate the efficacy and safety of sugarcane bagasse dietary fiber as an adjuvant therapy for improving quality of life in patients with stable chronic obstructive pulmonary disease (COPD).MethodsThis was a multicenter, randomized, double-blind, placebo-controlled trial. A total of 196 participants were randomized into a trial group (treated with 6 g/day sugarcane bagasse plus conventional treatment, n = 98) and a control group (treated with placebo plus conventional treatment, n = 98). All efficacy analyses were performed according to the intention-to-treat (ITT) principle. A per-protocol analysis set (PPS) was used to analyze the cases that completed the clinical trial with good compliance. The trial period was 30 days, with a 6-month follow-up. Pre- and post-treatment pulmonary symptom scores (cough, sputum, wheezing, and dyspnea) were recorded for both groups. The St. George's Respiratory Questionnaire (SGRQ) and the modified Medical Research Council (mMRC) dyspnea scale were assessed before treatment and at the end of the 6-month follow-up.ResultsThe ITT population was 178 and the PPS population was 166. Post-treatment pulmonary clinical symptoms and severity of dyspnea (mMRC and SGRQ evaluation) were significantly improved in both the trial group and the control group (ITT and PPS: P < 0.05). However, there was no statistical difference between the two groups in post-treatment pulmonary symptoms and mMRC. There was a greater reduction in the SGRQ subscales of activity, effect and total score in the trial group compared with the control group (ITT and PPS: P < 0.01). There was no statistical difference in pre- and post-treatment safety variables in either group.ConclusionSugarcane bagasse combined with conventional treatment improved quality of life in patients with stable COPD. Sugarcane bagasse appears to be a safe herbal medicine with potential for treating patients with stable COPD when taken orally as an adjuvant therapy

SHP2 phosphatase as a novel therapeutic target for melanoma treatment

Melanoma ranks among the most aggressive and deadly human cancers. Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses. Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment. Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis. We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation. Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment